Skip to main content

RELB KO cell lysate available now. KO validated by Western blot. Free of charge wild type control included. Knockout achieved by using CRISPR/Cas9, Homozygous: 65 bp deletion in exon4.

Be the first to review this product! Submit a review

Images

Western blot - Human RELB (Rel B) knockout HeLa cell lysate (AB257635), expandable thumbnail
  • Sanger Sequencing - Human RELB (Rel B) knockout HeLa cell lysate (AB257635), expandable thumbnail

Key facts

Cell type
HeLa
Species or organism
Human
Tissue
Cervix
Knockout validation
Sanger Sequencing, Western blot
Mutation description
Knockout achieved by using CRISPR/Cas9, Homozygous: 65 bp deletion in exon4.

Alternative names

I-Rel, Nuclear factor of kappa light polypeptide gene enhancer in B-cells 3, RELB_HUMAN, Reticuloendotheliosis viral oncogene homolog B, Transcription factor Rel B, v rel avian reticuloendotheliosis viral oncogene homolog B, v rel reticuloendotheliosis viral oncogene homolog B

What's included?

1 Kit
Components
Human RELB knockout HeLa cell lysate
1 x 100 µg
Human wild-type HeLa cell lysate
1 x 100 µg

Recommended products

RELB KO cell lysate available now. KO validated by Western blot. Free of charge wild type control included. Knockout achieved by using CRISPR/Cas9, Homozygous: 65 bp deletion in exon4.

Key facts

Cell type
HeLa
Mutation description
Knockout achieved by using CRISPR/Cas9, Homozygous: 65 bp deletion in exon4.
Disease
Adenocarcinoma
Concentration
Loading...

Properties

Gene name
RELB
Gene editing type
Knockout
Gene editing method
CRISPR technology
Knockout validation
Sanger Sequencing, Western blot
Zygosity
Homozygous

Quality control

STR analysis
CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX

Cell culture

Biosafety level
EU: 2 US: 2
Adherent/suspension
Adherent
Gender
Female

Storage

Shipped at conditions
Ambient - Can Ship with Ice
Appropriate short-term storage conditions
-20°C
Appropriate long-term storage conditions
-20°C

Notes


Knockout cell lysate achieved by CRISPR/Cas9.

Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.

Lysate preparation: Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10). This means that the protein of interest is denatured. If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.

User storage instructions: Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.

This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our limited use license and patent pages.

Supplementary info

This supplementary information is collated from multiple sources and compiled automatically.
Activity summary

Rel B also known as RELB proto-oncogene is a member of the NF-κB family of transcription factors. This protein plays a significant role in regulating gene expression. Rel B has a molecular mass of approximately 68 kDa. It expresses in diverse tissues including lymphoid organs and epithelial cells. It generally resides in the cytoplasm and translocates to the nucleus upon activation.

Biological function summary

Rel B serves as a critical component of the alternative NF-κB signaling pathway. It often forms a complex with another NF-κB family member called p52. This complex controls the transcription of genes involved in the immune response cell survival and differentiation. Additionally Rel B contributes to the development of secondary lymphoid organs and modulation of immune responses.

Pathways

Rel B integrates into the non-canonical NF-κB signaling pathway also influencing the canonical pathway to a lesser extent. In the non-canonical pathway Rel B interacts with NIK and p100 to influence immune cell function. This involvement makes Rel B essential in processes like adaptive immunity and inflammatory responses. The protein p52 closely associates with Rel B aiding its activity in these pathways.

Associated diseases and disorders

Rel B has connections to autoimmune diseases and certain cancers. Abnormal Rel B activity can lead to chronic inflammation and contribute to conditions like rheumatoid arthritis. In cancer its deregulation associates with lymphomas where it may interact with other NF-κB proteins like p50 and RelA affecting cell proliferation and survival. Understanding Rel B in these contexts could provide insights into therapeutic targets.

Product promise

We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.

In the unlikely event of one of our products not working as expected, you are covered by our product promise.

Full details and terms and conditions can be found here:
Terms & Conditions.

2 product images

Downloads

Product protocols

For this product, it's our understanding that no specific protocols are required. You can:

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com